206 related articles for article (PubMed ID: 1725030)
21. Loop diuretics combined with an ACE inhibitor for treatment of hypertension: a study with furosemide, piretanide, and ramipril in spontaneously hypertensive rats.
Becker RH; Baldes L; Treudler M
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S35-9. PubMed ID: 2474099
[TBL] [Abstract][Full Text] [Related]
22. Effects of an angiotensin converting enzyme inhibitor, ramipril, on intracranial circulation in healthy volunteers. off.
Demolis P; Chalon S; Annane D; Duhaze P; Giudicelli JF
Br J Clin Pharmacol; 1992 Sep; 34(3):224-30. PubMed ID: 1327051
[TBL] [Abstract][Full Text] [Related]
23. Ramipril: a review of the new ACE inhibitor.
Mills TP
J Ark Med Soc; 1992 Feb; 88(9):437-40. PubMed ID: 1532570
[TBL] [Abstract][Full Text] [Related]
24. Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension.
Karlberg BE; Lindström T; Rosenqvist U; Ohman KP
Am J Cardiol; 1987 Apr; 59(10):104D-109D. PubMed ID: 3034016
[TBL] [Abstract][Full Text] [Related]
25. The renin-angiotensin system and ramipril, a new converting enzyme inhibitor.
Vasmant D; Bender N
J Cardiovasc Pharmacol; 1989; 14 Suppl 4():S46-52. PubMed ID: 2483429
[TBL] [Abstract][Full Text] [Related]
26. Effect of ramipril on 24-hour variability of blood pressure and heart rate in essential hypertension.
Tochikubo O; Asahina S; Kaneko Y
Am J Cardiol; 1987 Apr; 59(10):83D-85D. PubMed ID: 3034039
[TBL] [Abstract][Full Text] [Related]
27. Assessment of the acute arterial effects of converting enzyme inhibition in essential hypertension: a double-blind, comparative and crossover study.
Topouchian J; Brisac AM; Pannier B; Vicaut E; Safar M; Asmar R
J Hum Hypertens; 1998 Mar; 12(3):181-7. PubMed ID: 9579768
[TBL] [Abstract][Full Text] [Related]
28. Metabolic effects of ramipril treatment in hypertensive subjects with non-insulin-dependent diabetes mellitus.
Janka HU; Nuber A; Mehnert H
Arzneimittelforschung; 1990 Apr; 40(4):432-5. PubMed ID: 2141472
[TBL] [Abstract][Full Text] [Related]
29. Effect of ramipril, a new angiotensin converting enzyme inhibitor, on diurnal variations of blood pressure in essential hypertension.
Kaneko Y; Omae T; Yoshinaga K; Iimura O; Inagaki Y; Ishii M; Saruta T; Yamada K; Kumahara Y; Ito K
Am J Cardiol; 1987 Apr; 59(10):86D-91D. PubMed ID: 3034040
[TBL] [Abstract][Full Text] [Related]
30. Small doses of ramipril to reduce microalbuminuria in diabetic patients with incipient nephropathy independently of blood pressure changes.
Marre M; Hallab M; Billiard A; Le Jeune JJ; Bled F; Girault A; Fressinaud P
J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S165-8. PubMed ID: 1725033
[TBL] [Abstract][Full Text] [Related]
31. Antihypertensive action and inhibition of tissue converting enzyme (CE) by three prodrug CE inhibitors, enalapril, ramipril and perindopril in stroke-prone spontaneously hypertensive rats.
Moursi MG; Ganten D; Lang RE; Unger T
J Hypertens Suppl; 1986 Oct; 4(3):S495-8. PubMed ID: 3023591
[TBL] [Abstract][Full Text] [Related]
32. Effects of a long-term treatment with aliskiren or ramipril on structural alterations of subcutaneous small-resistance arteries of diabetic hypertensive patients.
De Ciuceis C; Savoia C; Arrabito E; Porteri E; Mazza M; Rossini C; Duse S; Semeraro F; Agabiti Rosei C; Alonzo A; Sada L; La Boria E; Sarkar A; Petroboni B; Mercantini P; Volpe M; Rizzoni D; Agabiti Rosei E
Hypertension; 2014 Oct; 64(4):717-24. PubMed ID: 24980672
[TBL] [Abstract][Full Text] [Related]
33. Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril.
Predel HG; Düsing R; Bäcker A; Kipnowski J; Kramer HJ
Am J Cardiol; 1987 Apr; 59(10):143D-148D. PubMed ID: 3034023
[TBL] [Abstract][Full Text] [Related]
34. Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery?
Hirata K; Vlachopoulos C; Adji A; O'Rourke MF
J Hypertens; 2005 Mar; 23(3):551-6. PubMed ID: 15716696
[TBL] [Abstract][Full Text] [Related]
35. Ambulatory 24-h blood pressure monitoring in essential hypertensives treated with the angiotensin-converting enzyme inhibitor ramipril.
Spieker C; Zidek W; Vetter H; Rahn KH
J Int Med Res; 1991; 19(1):39-43. PubMed ID: 1826891
[TBL] [Abstract][Full Text] [Related]
36. [Antihypertensive action and inhibition of tissue conversion enzyme by ramipril, perindopril and enalapril in the spontaneously hypertensive rat (SHRSP)].
Unger T; Moursi MG; Lebrun C; Ganten D; Lang RE
Arch Mal Coeur Vaiss; 1986 Jun; 79(6):971-4. PubMed ID: 3026275
[TBL] [Abstract][Full Text] [Related]
37. Assessment of the efficacy, tolerance, and safety of ramipril in diabetic patients with mild-to-moderate hypertension: a retrospective analysis.
Erhard W; Lindner U; Krall H; Breitstadt A; Pfeiffer C
J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S160-4. PubMed ID: 1725032
[TBL] [Abstract][Full Text] [Related]
38. Comparison of response rates to the angiotensin-converting enzyme inhibitor ramipril in mild-to-moderate hypertension in a double-blind, parallel-group study and an open single-blind study.
Vasmant D; Lendresse P; Lemarie JC; Gallet M
J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S144-6. PubMed ID: 1725027
[TBL] [Abstract][Full Text] [Related]
39. Role of kallikrein-kinin system in the hypotensive mechanisms of converting enzyme inhibitors in essential hypertension.
Iimura O; Shimamoto K
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S63-6. PubMed ID: 2474107
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamic effects of a single 10-mg dose of the angiotensin converting enzyme inhibitor ramipril in patients with impaired renal function.
Ocón-Pujadas J; Debusmann ER; Jane F; Lahn W; Irmisch R; Mora J; Grötsch H
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S45-8. PubMed ID: 2474101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
